Related Experiment Video
Updated: Mar 25, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Improved endothelial function in heart failure outpatients with reduced ejection fraction after vericiguat therapy
Michele Correale1, Federica Santagata2, Damiano D'Alessandro2
1Emergency and Urgency Department, Ospedali Riuniti University Hospital.
Background:
Vericiguat, a soluble guanylate cyclase stimulator, has been shown to be effective in improving the prognosis of patients with heart failure with reduced ejection fraction (HFrEF) and worsening heart failure. We sought to evaluate possible changes in endothelial function assessed by flow-mediated dilation (FMD) in patients with HFrEF treated with vericiguat.
Results:
Improved FMD values were found after 3 months of therapy with vericiguat (19 ± 11 vs. 15 ± 10% FMD, P = 0.04). FMD variation at follow-up was inversely related to baseline FMD values ( r = -0.52, P = 0.001).
Major Findings:
Three months of therapy with vericiguat in patients with HFrEF and worsening heart failure were associated with improved endothelial function assessed by FMD.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
02:47Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: β-Blockers
Heart Failure II: Pathophysiology